| REPORT ATTRIBUTE |
DETAILS |
| Historical Period |
2019-2022 |
| Base Year |
2024 |
| Forecast Period |
2024-2032 |
| Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Market Size 2024 |
USD 3,852.5 million |
| Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Market, CAGR |
5.50% |
| Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Market Size 2032 |
USD 5,912.38 million |
Market Overview
The Global Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Market is projected to grow from USD 3,852.5 million in 2023 to an estimated USD 5,912.38 million by 2032, with a compound annual growth rate (CAGR) of 5.50% from 2024 to 2032. This growth is driven by the increasing incidence of bacterial infections, advancements in antibiotic therapies, and rising awareness among healthcare professionals and patients about early diagnosis and treatment.Key drivers fueling the ABSSSI market include the rising demand for effective and advanced treatments, an increase in hospital-acquired infections, and the expansion of healthcare infrastructure in emerging markets. Industry trends reveal a growing focus on novel therapies, combination drug formulations, and the use of more efficient and broad-spectrum antibiotics. The surge in R&D investments aimed at addressing antibiotic resistance is also significantly shaping the market’s landscape.Geographically, North America dominates the ABSSSI market due to the region’s well-established healthcare infrastructure and high incidence of skin infections. Europe follows closely, driven by similar factors. Meanwhile, the Asia-Pacific region is expected to witness the fastest growth due to increasing healthcare investments and improving access to quality treatment. Key players in the market include Merck & Co., Pfizer Inc., MELINTA THERAPEUTICS, Inc., ALLERGAN, Paratek Pharmaceuticals, Inc., and Teva Pharmaceutical Industries Ltd., all of whom are driving innovation through strategic partnerships and product launches.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research!
Download Sample
Market Drivers
Rising Incidence of ABSSSI and Antibiotic-Resistant Bacteria
One of the most significant drivers of the global ABSSSI market is the increasing incidence of acute bacterial skin and skin structure infections, particularly those caused by resistant bacterial strains. As healthcare systems worldwide face the challenge of rising antibiotic resistance, the need for effective and targeted treatments for bacterial infections, including ABSSSI, has surged. Infections caused by Methicillin-resistant Staphylococcus aureus (MRSA) and other resistant organisms are on the rise, leading to prolonged hospital stays, higher treatment costs, and more complex treatment protocols. The growing prevalence of antibiotic resistance has heightened the need for new antibiotics and alternative treatments that can address this critical issue. This demand is driving pharmaceutical companies to invest heavily in research and development (R&D) to develop novel therapies that can combat resistant bacteria effectively. For instance, in the U.S., more than 2.8 million antimicrobial-resistant infections occur each year, resulting in over 35,000 deaths. Additionally, infections caused by Methicillin-resistant Staphylococcus aureus (MRSA) have increased significantly, with MRSA accounting for a substantial proportion of hospital-acquired infections. Furthermore, the World Health Organization (WHO) estimates that antimicrobial resistance could cause up to 10 million deaths annually by 2050 if not addressed. Moreover, the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) have emphasized the urgent need for new antibiotics to address the escalating threat of antibiotic-resistant infections. This focus on antimicrobial resistance (AMR) is fostering a favorable regulatory environment that encourages the approval and commercialization of new treatments, which, in turn, propels the ABSSSI market forward. Governments and global health organizations are also increasingly providing funding and incentives to support the development of novel antibiotics, further stimulating market growth.
Advancements in Antibiotic Therapies and Drug Development
The ongoing advancements in antibiotic therapies and drug development are another key driver of the ABSSSI market. Over the past few years, there has been a significant focus on the development of new antibiotics and novel formulations aimed at improving the efficacy of treatment for bacterial skin infections. Pharmaceutical companies are concentrating on creating broad-spectrum antibiotics that can target multiple bacterial pathogens while minimizing side effects and reducing the risk of resistance development. Innovations such as combination therapies, which use two or more antibiotics to enhance treatment outcomes, have shown promising results in treating ABSSSI, especially in cases involving multi-drug-resistant bacteria. For instance, the U.S. Food and Drug Administration (FDA) approved Zevtera (ceftobiprole medocaril sodium) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in April 2024. Additionally, the use of combination therapies, such as vancomycin and aztreonam, has shown promising results in treating ABSSSI, especially in cases involving multi-drug-resistant bacteria. Furthermore, the development of intravenous-to-oral switch therapy has significantly reduced the length of hospital stays for patients with ABSSSI. Furthermore, the development of novel drug delivery mechanisms, such as intravenous-to-oral switch therapy, is enhancing patient compliance and reducing the length of hospital stays. These innovations not only improve patient outcomes but also reduce the burden on healthcare systems by minimizing the need for prolonged hospitalization. The introduction of newer antibiotics, such as those from the oxazolidinone and cephalosporin classes, is also expanding the treatment landscape for ABSSSI, offering clinicians a broader range of therapeutic options. As pharmaceutical companies continue to invest in R&D to address the growing threat of resistant infections, the ABSSSI market is expected to see sustained growth in the coming years.
Increasing Healthcare Infrastructure in Emerging Markets
The expansion of healthcare infrastructure, particularly in emerging markets, is another crucial driver of the ABSSSI market. Developing economies in regions such as Asia-Pacific, Latin America, and the Middle East are witnessing significant improvements in their healthcare systems, which is leading to better access to advanced medical treatments, including those for bacterial infections. Governments in these regions are investing heavily in building hospitals, clinics, and healthcare facilities, as well as improving the availability of diagnostic tools and treatment options for infectious diseases like ABSSSI. For instance, in the Asia-Pacific region, healthcare spending is projected to account for more than 20% of global spending by 2030. Additionally, in Latin America and the Caribbean, investments in telemedicine and telehealth services have expanded access to care during pandemic peaks. Furthermore, the World Health Organization (WHO) estimates that investing an additional USD 200 billion annually in primary healthcare across low and middle-income countries could save 60 million lives and increase average life expectancy by 3.7 years by 2030. In addition to infrastructure development, the rising awareness of healthcare professionals and patients about the importance of early diagnosis and effective treatment of bacterial infections is contributing to increased demand for antibiotics and related therapies. As healthcare access improves and more people seek medical treatment for skin infections, the demand for ABSSSI therapies is expected to grow. Moreover, the rising prevalence of chronic diseases, such as diabetes, which can lead to complications like skin infections, further underscores the need for effective treatment options in these regions. This increasing healthcare infrastructure and access in emerging markets are poised to provide lucrative opportunities for pharmaceutical companies operating in the ABSSSI market.
Regulatory Support and Government Initiatives
Regulatory support and government initiatives aimed at combating antibiotic resistance and improving public health are playing a significant role in driving the ABSSSI market. In response to the growing threat of resistant infections, regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others have introduced streamlined approval processes for new antibiotics, especially those targeting multi-drug-resistant organisms. These regulatory incentives are encouraging pharmaceutical companies to accelerate the development of innovative therapies for ABSSSI. Additionally, government programs and initiatives that focus on antibiotic stewardship and infection control are creating a favorable environment for market growth. Many countries have implemented national action plans to tackle antimicrobial resistance, which include measures to promote the responsible use of antibiotics, improve infection prevention, and support the development of new treatment options. The inclusion of ABSSSI in these public health agendas is helping to raise awareness about the importance of addressing bacterial skin infections and ensuring that effective treatments are available to those who need them.
Market Trends
Increasing Focus on Novel Antibiotics and Combination Therapies
One of the most prominent trends in the ABSSSI market is the growing emphasis on the development of novel antibiotics and combination therapies to combat antibiotic-resistant bacteria. As traditional antibiotics lose efficacy due to the rise of resistant bacterial strains such as Methicillin-resistant Staphylococcus aureus (MRSA), pharmaceutical companies are prioritizing the creation of new antibiotics that can target a broader spectrum of pathogens. These innovative therapies are designed to address the growing issue of multi-drug resistance, offering clinicians more effective options for treating complex ABSSSI cases. For instance, the U.S. Food and Drug Administration (FDA) approved Zevtera (ceftobiprole medocaril sodium) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in April 2024. Additionally, the use of combination therapies, such as vancomycin and aztreonam, has shown promising results in treating ABSSSI, especially in cases involving multi-drug-resistant bacteria. Furthermore, the development of intravenous-to-oral switch therapy has significantly reduced the length of hospital stays for patients with ABSSSI. Combination therapies, which involve the use of two or more antibiotics or a combination of antibiotics with other antimicrobial agents, are also gaining traction in the market. These therapies are designed to enhance treatment efficacy, reduce the likelihood of resistance development, and shorten the duration of treatment. For instance, combination regimens using new cephalosporins or glycopeptides with older antibiotics have shown promise in improving patient outcomes. This trend is likely to continue as companies focus on addressing the unmet medical needs of patients with resistant infections and gaining a competitive edge in the market.
Shift Towards Outpatient Treatment and Oral Antibiotics
Another emerging trend in the ABSSSI market is the shift from inpatient care to outpatient treatment, driven by the introduction of highly effective oral antibiotics. Historically, ABSSSI treatments required prolonged hospital stays and intravenous (IV) antibiotic administration. However, recent advancements in drug formulations have led to the development of oral antibiotics that offer similar efficacy to IV drugs, allowing patients to receive treatment in outpatient settings or even at home. This shift is not only improving patient convenience and compliance but also reducing the burden on healthcare facilities by lowering hospitalization rates. Oral antibiotics such as tedizolid and delafloxacin are gaining popularity due to their effectiveness in treating resistant bacterial infections while minimizing adverse effects. This transition is also cost-effective for healthcare systems, as it reduces the need for extended hospital stays and resource-intensive IV treatments. As more patients and healthcare providers recognize the benefits of oral therapies, the demand for these treatments is expected to increase, further shaping the dynamics of the ABSSSI market.
Market Restraints and Challenges
Rising Antibiotic Resistance and Limited Novel Drug Development
One of the most significant challenges facing the Global ABSSSI market is the growing issue of antibiotic resistance, which limits the effectiveness of existing treatments. The rapid evolution of resistant bacterial strains, such as Methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE), has rendered many traditional antibiotics ineffective. This has made it increasingly difficult to treat ABSSSI cases, particularly those involving multi-drug-resistant pathogens. While the demand for new antibiotics is high, the development pipeline for novel antimicrobial agents remains limited. Pharmaceutical companies face high costs, stringent regulatory hurdles, and lengthy development timelines when creating new antibiotics. The commercial viability of these drugs is also a concern, as antibiotics are often used sparingly to prevent resistance, which can limit their profitability. These factors collectively hinder the introduction of new, effective therapies into the market, posing a significant restraint to market growth.
High Cost of Treatment and Limited Access in Low-Income Regions
The high cost associated with ABSSSI treatments, especially those involving advanced antibiotics and combination therapies, presents another key challenge in the market. Newer antibiotics, while effective, often come with a premium price tag, making them less accessible to patients in low- and middle-income countries. This is further compounded by the lack of robust healthcare infrastructure in many regions, limiting access to timely diagnosis and treatment for bacterial skin infections. Additionally, the cost of prolonged hospital stays for patients requiring intravenous (IV) antibiotics or advanced care for resistant infections adds to the financial burden on healthcare systems and patients alike. For many governments and healthcare providers in resource-limited settings, the cost of these treatments is a significant barrier, restricting their ability to adopt newer therapies. This lack of accessibility, particularly in developing countries, is a major restraint on the global expansion of the ABSSSI market.
Market Segmentation Analysis
By Infection Type
The ABSSSI market can be segmented by infection type into hospital-acquired and community-acquired infections. Hospital-acquired ABSSSI typically occurs in healthcare settings like hospitals or nursing homes, often involving more severe infections due to the prevalence of drug-resistant bacterial strains, such as Methicillin-resistant Staphylococcus aureus (MRSA). The increasing incidence of these infections, alongside the growing number of surgeries and invasive procedures, is driving demand for broad-spectrum antibiotics and newer therapies to combat these resistant strains. On the other hand, community-acquired ABSSSI refers to infections contracted outside healthcare facilities, affecting individuals without recent hospital exposure. Although these infections are generally less resistant to antibiotics, the rise of drug-resistant strains in community settings is leading to a growing need for accessible and effective treatment options, driving steady growth in this segment.
By Route of Administration
The route of administration in the ABSSSI market is divided into oral and parenteral options. Oral administration is gaining popularity due to its convenience, cost-effectiveness, and effectiveness in treating community-acquired ABSSSI cases. Potent oral antibiotics like tedizolid and delafloxacin allow for effective treatment without hospitalization, boosting demand as more patients shift towards outpatient care and home-based treatments, reducing the need for intravenous (IV) administration. Parenteral administration, however, remains crucial for severe or hospital-acquired ABSSSI cases, particularly when rapid treatment is required for drug-resistant infections. While IV treatments are vital in hospitals for critical patients, the increasing availability of effective oral alternatives may gradually reduce the reliance on parenteral administration in the future.
Segments
Based on Infection Type
- Hospital-acquired ABSSSI
- Community-acquired ABSSSI
Based on Route of Administration
Based on Distribution Channel
- Hospitals Pharmacy
- Retail Pharmacy
- Online Pharmacy
Based on Region
- North America
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- UK
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Regional Analysis
North America (35%)
North America holds the largest share of the global ABSSSI market, accounting for approximately 35% of the total market. This dominance is primarily due to the region’s well-established healthcare infrastructure, high prevalence of hospital-acquired infections, and the presence of key market players like Pfizer Inc., Merck & Co., and Cumberland Pharmaceuticals. The U.S. leads the North American market, driven by the increasing cases of Methicillin-resistant Staphylococcus aureus (MRSA) infections, which require advanced antibiotics and treatment protocols. Furthermore, the region benefits from strong research and development activities, along with favorable regulatory frameworks that support the approval of novel therapies. High healthcare expenditure and the growing use of advanced diagnostic tools are also contributing to the sustained market growth in this region.
Europe (28%)
Europe accounts for around 28% of the global ABSSSI market, making it the second-largest region. The market here is fueled by a rising incidence of bacterial infections, growing awareness among healthcare providers about resistant pathogens, and increasing investments in healthcare infrastructure. Countries like Germany, France, and the UK lead the European market, with significant contributions from both public and private healthcare sectors. The European Medicines Agency (EMA) has been proactive in supporting the development of novel antibiotics, especially those targeting multi-drug-resistant organisms, which has spurred market growth. However, the region faces challenges related to stringent regulatory approvals and pricing pressures that can slow down the commercialization of newer treatments.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
Key players
- Merck & Co., Inc.
- Pfizer Inc.
- MELINTA THERAPEUTICS, INC.
- ALLERGAN
- Paratek Pharmaceuticals, Inc.
- Cumberland Pharmaceuticals Inc.
- Teva Pharmaceutical Industries Ltd
Competitive Analysis
The Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) market is highly competitive, with several prominent players leading innovation and market expansion. Merck & Co. and Pfizer Inc. dominate due to their broad portfolios of antibiotics and extensive global reach. MELINTA THERAPEUTICS, known for its focus on antibiotic resistance, continues to drive growth by developing novel therapies targeting resistant bacterial strains. ALLERGAN and Paratek Pharmaceuticals are key players, leveraging their strengths in research and development to offer effective treatments for ABSSSI. Cumberland Pharmaceuticals and Teva Pharmaceutical Industries also maintain significant market shares by offering cost-effective and widely accessible antibiotics. As the market grows, companies are increasingly focusing on R&D, strategic partnerships, and product differentiation to gain competitive advantages, particularly in addressing antibiotic resistance and enhancing treatment efficacy. This intense competition is expected to stimulate further innovation in the ABSSSI market.
Recent Developments
- March 15, 2021, Melinta Therapeutics announced FDA approval of KIMYRSA (oritavancin) for the treatment of adult patients with ABSSSI caused by susceptible isolates of designated Gram-positive microorganisms, including methicillin-resistant Staphylococcus aureus (MRSA).
- April 22, 2022, Allergan’s Teflaro (ceftaroline fosamil) received an updated label from the FDA for the treatment of adult patients with ABSSSI and community-acquired bacterial pneumonia (CABP)
- September 21, 2023, Gurnet Point Capital and Novo Holdings A/S completed the acquisition of Paratek Pharmaceuticals, Inc. Paratek’s lead commercial product, NUZYRA (omadacycline), is available for the treatment of adults with ABSSSI.
- August 6, 2024, Cumberland Pharmaceuticals reported significant financial growth and highlighted the effectiveness of Vibativ (telavancin) as a treatment for ABSSSI.
- October 3, 2024, Teva expanded its strategic partnership with mAbxience to include an additional oncology biosimilar candidate, reinforcing its commitment to providing high-quality treatment.
Market Concentration and Characteristics
The Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) market is moderately concentrated, with a mix of large pharmaceutical companies and smaller specialized firms contributing to the competitive landscape. Key players such as Merck & Co., Pfizer, and Teva Pharmaceutical Industries hold significant market shares due to their established portfolios and global presence. However, smaller companies like MELINTA THERAPEUTICS and Paratek Pharmaceuticals also play a critical role, particularly in developing innovative therapies targeting antibiotic-resistant bacterial strains. The market is characterized by high R&D intensity, driven by the urgent need to address antibiotic resistance and develop novel treatments. Additionally, strategic partnerships, mergers, and acquisitions are common as companies seek to expand their product offerings and gain competitive advantages in this growing market.
Report Coverage
The research report offers an in-depth analysis based on Infection Type, Route of Administration, Distribution Channel and Region. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.
Future Outlook
- The growing prevalence of antibiotic-resistant bacterial strains will drive the demand for novel antibiotics, pushing pharmaceutical companies to accelerate their research and development efforts.
- Governments and healthcare organizations will intensify efforts to combat antimicrobial resistance, leading to greater regulatory support for the development and approval of innovative therapies.
- Combination therapies that enhance treatment efficacy and minimize resistance will become increasingly popular, offering improved outcomes for patients with resistant ABSSSI cases.
- The continued development of effective oral antibiotics will facilitate a shift from inpatient to outpatient care, reducing hospitalization rates and making treatments more accessible.
- Rapid improvements in healthcare infrastructure and access to advanced treatments in emerging markets such as Asia-Pacific and Latin America will create new growth opportunities for ABSSSI therapies.
- The rise of telemedicine and digital healthcare will support remote diagnosis and treatment of ABSSSI, making it easier for patients to access care and prescriptions, particularly in rural areas.
- Regulatory bodies will continue to streamline approval processes for new antibiotics, encouraging pharmaceutical companies to invest in innovative therapies aimed at addressing drug-resistant infections.
- Advances in diagnostic tools and treatment protocols will enable more personalized approaches to ABSSSI treatment, improving patient outcomes by targeting specific pathogens more effectively.
- Collaboration between governments, research institutions, and pharmaceutical companies will grow, focusing on joint efforts to tackle the global challenge of antibiotic resistance and improve treatment options.
- Despite advancements, high treatment costs will remain a challenge in low-income regions, necessitating efforts to improve affordability and access to advanced antibiotics through global health initiatives.
